CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleMarket cap is $3.34B, above the global median of $1.18B
- FinancialsAltman Z-Score 2.8: safe zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
1.33%Below 5Y avg (2.05%)
Annual Rate
CNY 0.16Paid annual
Payout Ratio
66.1%Moderate
Payback Period
70.4 yr
Last Ex-Dividend
Jun 26, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
22.49BCNY3.34B · vs all stocks (USD)
Trailing P/E
28.27xvs Medical Devices peers
Revenue (TTM)
6.42BCNY953.28M · vs all stocks (USD)
Profit Margin
12.94%vs Medical Devices peers
Beta
0.0520xvs all stocks
52-Week Change
-33.70%vs all stocks
Market Capitalization
22.49BCNY3.34B · vs all stocks (USD)
Enterprise Value
26.64BCNY3.96B · vs all stocks (USD)
Trailing P/E
28.27xvs Medical Devices peers
Forward P/E
17.67xvs Medical Devices peers
Price to Sales (TTM)
3.65xvs Medical Devices peers
Price to Book (MRQ)
1.43xvs Medical Devices peers
Enterprise to Revenue
4.15xvs Medical Devices peers
Enterprise to EBITDA
11.90xvs Medical Devices peers
Gross Margin
62.03%vs Medical Devices peers
Profit Margin
12.94%vs Medical Devices peers
Operating Margin
24.10%vs Medical Devices peers
Return on Assets (TTM)
2.90%vs Medical Devices peers
Return on Equity (TTM)
4.92%vs Medical Devices peers
Revenue (TTM)
6.42BCNY953.28M · vs all stocks (USD)
Revenue per Share (TTM)
3.48CNYUpdated Aug 19, 2026Quarterly Revenue Growth
-3.70%vs Medical Devices peers
Gross Profit (TTM)
3.96BCNY588.62M · vs all stocks (USD)
EBITDA (TTM)
1.65BCNY244.69M · vs all stocks (USD)
Net Income (TTM)
830.28MCNY123.31M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-34.80%vs Medical Devices peers
Operating Cash Flow (TTM)
1.37BCNY203.89M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
70.64MCNY10.49M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.1628CNYUpdated Aug 19, 2026Trailing Annual Dividend Yield
1.33%vs all stocks
5-Year Average Dividend Yield
2.05%vs all stocks
Payout Ratio
66.09%vs Medical Devices peers
Minority Interest (Equity)
1.64BCNYFY2025 · Dec 31, 2025Revenue
6.48BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
2.33BCNYFY2025 · Dec 31, 2025Gross Profit
4.15BCNYFY2025 · Dec 31, 2025Operating Income
1.54BCNY228.51M · vs all stocks (USD)
Pre-tax Income
1.22BCNYFY2025 · Dec 31, 2025Income Tax Expense
197.07MCNYFY2025 · Dec 31, 2025Net Income
1.02BCNYFY2025 · Dec 31, 2025EBIT
1.39BCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
2.24BCNYFY2025 · Dec 31, 2025Research & Development
792.38MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
787.65MCNYFY2025 · Dec 31, 2025Other Operating Expenses
86.07MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
71.51MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
176.64MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.5219CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.5219CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
1.84BSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
1.84BSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
1.02BCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
-57.00MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
550.35MCNYFY2025 · Dec 31, 2025Free Cash Flow
-91.08MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
4.34BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
1.02BCNYFY2025 · Dec 31, 2025Other Non-cash Items
260.10MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-489.63MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-239.12MCNYFY2025 · Dec 31, 2025Capital Expenditures
-641.43MCNYFY2025 · Dec 31, 2025Net Acquisitions
2.90MCNYFY2025 · Dec 31, 2025Purchase of Investments
-1.07BCNYFY2025 · Dec 31, 2025Sale of Investments
896.96MCNYFY2025 · Dec 31, 2025Other Investing Activity
116.74MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-690.74MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
3.15BCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-2.52BCNYFY2025 · Dec 31, 2025Common Dividends Paid
-681.55MCNYFY2025 · Dec 31, 2025Other Financing Charges
32.63MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-17.67MCNYFY2025 · Dec 31, 2025Shares Outstanding
1.84BSharesUpdated Aug 19, 2026Float Shares
1.13BSharesUpdated Aug 19, 2026% Held by Insiders
38.64%vs all stocks
% Held by Institutions
11.21%vs all stocks
Total Cash (MRQ)
3.99BCNY592.62M · vs all stocks (USD)
Total Cash per Share (MRQ)
2.17CNYUpdated Aug 19, 2026Total Debt (MRQ)
5.65BCNY839.15M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.3143xvs Medical Devices peers
Current Ratio (MRQ)
2.38xvs Medical Devices peers
Book Value per Share (MRQ)
8.92CNYUpdated Aug 19, 2026Total Assets
26.14BCNY3.88B · vs all stocks (USD)
Total Current Assets
10.00BCNYFY2025 · Dec 31, 2025Total Liabilities
8.38BCNYFY2025 · Dec 31, 2025Total Non-current Assets
16.14BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
3.42BCNYFY2025 · Dec 31, 2025Total Current Liabilities
4.96BCNYFY2025 · Dec 31, 2025Cash
4.11BCNYFY2025 · Dec 31, 2025Cash Equivalents
316.72MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
4.43BCNYFY2025 · Dec 31, 2025Other Short-term Investments
203.31MCNYFY2025 · Dec 31, 2025Accounts Receivable
1.99BCNYFY2025 · Dec 31, 2025Inventory
2.02BCNYFY2025 · Dec 31, 2025Accounts Payable
755.04MCNYFY2025 · Dec 31, 2025Short-term Debt
3.25BCNYFY2025 · Dec 31, 2025Other Current Liabilities
79.94MCNYFY2025 · Dec 31, 2025Long-term Debt
3.13BCNYFY2025 · Dec 31, 2025Common Stock (Book)
1.84BCNYFY2025 · Dec 31, 2025Retained Earnings
9.99BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
17.76BCNY2.64B · vs all stocks (USD)
52-Week Low
11.01CNYUpdated Aug 19, 202652-Week High
21.60CNYUpdated Aug 19, 202652-Week Change
-33.70%vs all stocks
Beta
0.0520xvs all stocks
50-Day MA
12.45CNYUpdated Aug 19, 2026200-Day MA
15.40CNYUpdated Aug 19, 2026Avg 10-Day Volume
34.18MSharesUpdated Aug 19, 2026Avg 30-Day Volume
34.60MSharesUpdated Aug 19, 2026Diluted EPS (TTM)
0.4500CNYUpdated Aug 19, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 2.8: safe zoneNotable
Altman Z-Score: 2.80
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Market cap is $3.34B, above the global median of $1.18BNotable
Market cap (USD): 3,340,182,353.578Global Median: 1,179,398,897.704
Revenue is $953.28M, above the global median of $534.05MNotable
Revenue (USD): 953,284,759.327Global Median: 534,052,387.958
Companies that share the same coordination system — how they create, deliver, or capture value.
Wockhardt Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Harbin Pharmaceutical Group Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Hebei Changshan Biochemical Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Immunome Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Tasly Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
uniQure N.V.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Jiangsu Nhwa Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hubei Jumpcan Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Betta Pharmaceuticals Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
ABL Bio Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
Guangzhou Kingteller Technology Co., Ltd.
1 interpretationIndustry-Benchmarked ROA and Margin Elevated
CIE Automotive India Ltd.
1 interpretationIndustry-Benchmarked ROA and Margin Elevated
Hansol Chemical Co., Ltd.
1 interpretationIndustry-Benchmarked ROA and Margin Elevated